EP3307305A4 - Targeted adaptive vaccines - Google Patents
Targeted adaptive vaccines Download PDFInfo
- Publication number
- EP3307305A4 EP3307305A4 EP16808481.2A EP16808481A EP3307305A4 EP 3307305 A4 EP3307305 A4 EP 3307305A4 EP 16808481 A EP16808481 A EP 16808481A EP 3307305 A4 EP3307305 A4 EP 3307305A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- vaccines
- targeted adaptive
- adaptive
- targeted
- adaptive vaccines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562173783P | 2015-06-10 | 2015-06-10 | |
PCT/US2016/037095 WO2016201377A1 (en) | 2015-06-10 | 2016-06-10 | Targeted adaptive vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3307305A1 EP3307305A1 (en) | 2018-04-18 |
EP3307305A4 true EP3307305A4 (en) | 2019-05-22 |
Family
ID=57504553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16808481.2A Withdrawn EP3307305A4 (en) | 2015-06-10 | 2016-06-10 | Targeted adaptive vaccines |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3307305A4 (en) |
WO (1) | WO2016201377A1 (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012267531B2 (en) | 2011-06-08 | 2017-06-22 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EA201492055A1 (en) | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | INHALATIVE DELIVERY OF mRNA IN TIGHTNESS CELL TARGETS |
JP6586075B2 (en) | 2013-03-14 | 2019-10-02 | トランスレイト バイオ, インコーポレイテッド | Method for purifying messenger RNA |
AU2014239184B2 (en) | 2013-03-14 | 2018-11-08 | Translate Bio, Inc. | Methods and compositions for delivering mRNA coded antibodies |
HUE042640T2 (en) | 2013-03-14 | 2019-07-29 | Translate Bio Inc | Cftr mrna compositions and related methods and uses |
EP2972360B1 (en) | 2013-03-15 | 2018-03-07 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
EP3060258A1 (en) | 2013-10-22 | 2016-08-31 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
BR112016024644A2 (en) | 2014-04-23 | 2017-10-10 | Modernatx Inc | nucleic acid vaccines |
KR20220158867A (en) | 2014-04-25 | 2022-12-01 | 샤이어 휴먼 지네틱 테라피즈 인크. | Methods for purification of messenger rna |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
EP3324979B1 (en) | 2015-07-21 | 2022-10-12 | ModernaTX, Inc. | Infectious disease vaccines |
US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
MA45209A (en) | 2015-10-22 | 2019-04-17 | Modernatx Inc | VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES |
AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CA3002912A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
EP4349405A3 (en) | 2015-10-22 | 2024-06-19 | ModernaTX, Inc. | Respiratory virus vaccines |
EP3964200A1 (en) | 2015-12-10 | 2022-03-09 | ModernaTX, Inc. | Compositions and methods for delivery of therapeutic agents |
US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
AU2017248189B2 (en) | 2016-04-08 | 2021-04-29 | Translate Bio, Inc. | Multimeric coding nucleic acid and uses thereof |
MA45051A (en) | 2016-05-18 | 2019-03-27 | Modernatx Inc | RELAXIN-CODING POLYNUCLEOTIDES |
EP3469074B1 (en) | 2016-06-13 | 2020-12-09 | Translate Bio, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
EP4166666A1 (en) | 2016-09-14 | 2023-04-19 | ModernaTX, Inc. | High purity rna compositions and methods for preparation thereof |
EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | Human cytomegalovirus vaccine |
WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
CN110505877A (en) * | 2017-02-01 | 2019-11-26 | 摩登纳特斯有限公司 | RNA cancer vaccine |
EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | High potency immunogenic compositions |
WO2018157009A1 (en) * | 2017-02-24 | 2018-08-30 | Modernatx, Inc. | Nucleic acid-based therapy of muscular dystrophies |
EP3585417B1 (en) | 2017-02-27 | 2023-02-22 | Translate Bio, Inc. | Method of making a codon-optimized cftr mrna |
WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
MA47787A (en) | 2017-03-15 | 2020-01-22 | Modernatx Inc | RESPIRATORY SYNCYTIAL VIRUS VACCINE |
EP3609534A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Broad spectrum influenza virus vaccine |
WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
MA48047A (en) | 2017-04-05 | 2020-02-12 | Modernatx Inc | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
WO2018213476A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | Rna formulations |
US11912982B2 (en) | 2017-08-18 | 2024-02-27 | Modernatx, Inc. | Methods for HPLC analysis |
US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
MA49913A (en) | 2017-08-18 | 2021-05-05 | Modernatx Inc | RNA POLYMERASE VARIANTS |
AU2018326799A1 (en) | 2017-08-31 | 2020-02-27 | Modernatx, Inc. | Methods of making lipid nanoparticles |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
AU2018392716A1 (en) | 2017-12-20 | 2020-06-18 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
CN111902157B (en) * | 2018-03-21 | 2023-08-04 | 松阳生技股份有限公司 | Composition for promoting local muscle growth, slowing down or preventing local muscle atrophy and application thereof |
CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
WO2020047399A1 (en) * | 2018-08-31 | 2020-03-05 | Massachusetts Institute Of Technology | Ionizable lipidoids and their uses |
CN113271926A (en) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | Preparation of lipid nanoparticles and methods of administration thereof |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
JP2022521094A (en) | 2019-02-20 | 2022-04-05 | モデルナティエックス インコーポレイテッド | RNA polymerase variant for co-transcription capping |
WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
WO2021154947A1 (en) * | 2020-01-28 | 2021-08-05 | Ubi Ip Holdings | Peptide immunogens targeting pcsk9 and formulations thereof for prevention and treatment of pcsk9-mediated disorders |
CA3174215A1 (en) | 2020-04-22 | 2021-10-28 | Ugur Sahin | Coronavirus vaccine |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
WO2023230578A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating circulating factors |
WO2023230573A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of immune responses |
WO2023230570A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating genetic drivers |
WO2023230549A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of tumor suppressors and oncogenes |
WO2023230566A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating cytokines |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
WO2024129988A1 (en) | 2022-12-14 | 2024-06-20 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for delivery of therapeutic agents to bone |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140206852A1 (en) * | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides |
WO2015024666A1 (en) * | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Composition and vaccine for treating lung cancer |
WO2015085318A2 (en) * | 2013-12-06 | 2015-06-11 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8748493B2 (en) * | 2009-03-20 | 2014-06-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Inhibitors of cathepsin S for prevention or treatment of obesity-associated disorders |
-
2016
- 2016-06-10 WO PCT/US2016/037095 patent/WO2016201377A1/en active Application Filing
- 2016-06-10 EP EP16808481.2A patent/EP3307305A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140206852A1 (en) * | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides |
WO2015024666A1 (en) * | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Composition and vaccine for treating lung cancer |
WO2015085318A2 (en) * | 2013-12-06 | 2015-06-11 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
Non-Patent Citations (6)
Title |
---|
GERGANA GALABOVA ET AL: "Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management", PLOS ONE, vol. 9, no. 12, 4 December 2014 (2014-12-04), pages e114469, XP055579730, DOI: 10.1371/journal.pone.0114469 * |
NORBERT PARDI ET AL: "mRNA vaccines - a new era in vaccinology", NATURE REVIEWS. DRUG DISCOVERY, vol. 17, no. 4, 12 January 2018 (2018-01-12), GB, pages 261 - 279, XP055524319, ISSN: 1474-1776, DOI: 10.1038/nrd.2017.243 * |
PATRICK MIDOUX ET AL: "Lipid-based mRNA vaccine delivery systems", EXPERT REVIEW OF VACCINES, vol. 14, no. 2, 12 February 2015 (2015-02-12), GB, pages 221 - 234, XP055439935, ISSN: 1476-0584, DOI: 10.1586/14760584.2015.986104 * |
S. HOLTKAMP ET AL: "Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells", BLOOD, vol. 108, no. 13, 15 December 2006 (2006-12-15), pages 4009 - 4017, XP055044965, ISSN: 0006-4971, DOI: 10.1182/blood-2006-04-015024 * |
See also references of WO2016201377A1 * |
TOMPKINS STEPHEN MARK ET AL: "Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1", EMERGING INFECTIOUS DISE, EID, ATLANTA, GA, US, vol. 13, no. 3, 1 March 2007 (2007-03-01), pages 426 - 435, XP009089369, ISSN: 1080-6040 * |
Also Published As
Publication number | Publication date |
---|---|
EP3307305A1 (en) | 2018-04-18 |
WO2016201377A1 (en) | 2016-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3307305A4 (en) | Targeted adaptive vaccines | |
EP3076994A4 (en) | Targeted adaptive vaccines | |
EP3328873A4 (en) | Targeted oligonucleotides | |
EP3197057A4 (en) | Transceiver | |
EP3309423A4 (en) | Damper | |
EP3309424A4 (en) | Damper | |
EP3196502A4 (en) | Damper | |
EP3312431A4 (en) | Blower | |
EP3231644A4 (en) | Stabilizer | |
EP3351820A4 (en) | Damper | |
EP3296588A4 (en) | Damper | |
EP3164840A4 (en) | Enhanced near field communications attachment | |
EP2938045B8 (en) | Geopositioning method | |
EP3706787A4 (en) | Vaccine | |
EP3299636A4 (en) | Blower | |
EP3327473A4 (en) | Mode scrambler | |
EP3171052A4 (en) | Damper | |
AU2017904499A0 (en) | Vaccine | |
AU2017900446A0 (en) | Vaccine | |
AU2016902014A0 (en) | Vaccine | |
EP3290048A4 (en) | Immunity-inducing agent | |
AU2015901481A0 (en) | Schistosoma vaccine | |
AU2015902954A0 (en) | Totally adjustable wingsail | |
AU2015903147A0 (en) | FoLine | |
AU2015902786A0 (en) | SafeStick |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20180109 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190423 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/31 20060101ALI20190415BHEP Ipc: A61K 39/00 20060101AFI20190415BHEP Ipc: A61P 3/06 20060101ALI20190415BHEP Ipc: C12N 9/52 20060101ALI20190415BHEP Ipc: G01N 33/569 20060101ALI20190415BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20191121 |